+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Other thalidomide analogues and next-generation cereblon modulators), By Application (Multiple Myeloma, Autoimmune Disease, Hematological Malignancies, Other applications), and Regional Forecast, 2026-2034
The global thalidomide analogue market was valued at USD 11.50 billion in 2025 and is estimated at USD 11.14 billion in 2026. The market is projected to reach USD 8.63 billion by 2034, representing a -3.1% CAGR during 2026–2034.
Thalidomide analogues are immunomodulatory and cereblon-binding therapies used primarily in hematologic malignancies, led by lenalidomide and pomalidomide. Their commercial importance is concentrated in multiple myeloma, where oral immunomodulatory therapy has long been embedded in induction, maintenance and relapsed-disease treatment combinations.
The market is entering a value-contraction phase because generic lenalidomide is eroding the revenue of the former blockbuster Revlimid franchise. Bristol Myers Squibb reported 2025 Revlimid revenue of USD 3.0 billion, down sharply year over year, while Pomalyst/Imnovid generated USD 2.7 billion. Lower-priced generics increase treatment access and prescription volume but reduce the value captured per course.
At the same time, the mechanism is evolving rather than disappearing. New cereblon E3 ligase modulators extend the protein-degradation platform beyond first-generation IMiDs. In August 2026, the FDA approved iberdomide as ZENBEXUS in relapsed or refractory multiple myeloma, creating a new premium product class while mature lenalidomide value continues to decline.
Source: NCI/SEER myeloma statistics; Bristol Myers Squibb 2025 product revenues; ZENBEXUS approval announcement.
The study covers thalidomide-derived and related cereblon-directed analogue therapies included in the syndicated market scope, with analysis by principal product type, therapeutic application and geography.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Year | 2034 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million/billion |
| By Type | Revlimid (lenalidomide); Pomalyst/Imnovid (pomalidomide); Other thalidomide analogues and next-generation cereblon modulators |
| By Application | Multiple Myeloma; Autoimmune Disease; Hematological Malignancies; Other applications |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Key Market Players | Bristol Myers Squibb; Dr. Reddy's Laboratories; Teva Pharmaceutical Industries; Sun Pharmaceutical Industries; Aurobindo Pharma; Viatris; Shilpa Medicare; Torrent Pharmaceuticals; Hikma Pharmaceuticals; Jubilant Pharmova; Bio-Techne (R&D Systems); MedChemExpress; Cayman Chemical; Abcam (Danaher) |
The market includes commercial revenue from thalidomide analogues and related cereblon-directed therapies included in the report scope. Multiple myeloma is the principal demand base, with additional hematologic and specialty indications contributing smaller revenue pools.
Revenue from unrelated multiple-myeloma classes such as proteasome inhibitors, anti-CD38 antibodies, CAR-T therapies and bispecific antibodies is excluded. Combination-regimen partners are discussed only when they influence analogue demand, treatment sequencing or market access.
Loss of exclusivity has shifted lenalidomide from a high-concentration branded franchise toward multi-supplier generic competition. Bristol Myers Squibb's 2025 Revlimid revenue fell to USD 3.0 billion, demonstrating how price erosion can outweigh stable or rising treatment volume.
NCI/SEER estimates 36,000 new U.S. myeloma cases in 2026. Because multiple myeloma is commonly managed through sequential and combination therapy, patients may generate demand for immunomodulatory agents across induction, maintenance and relapsed settings.
Pomalyst/Imnovid generated USD 2.7 billion in worldwide revenue for Bristol Myers Squibb in 2025. Its continued commercial scale shows that differentiated later-line use can remain valuable even as lenalidomide genericization reshapes the overall category.
Lenalidomide and related agents carry strict pregnancy-prevention and risk-management requirements. FDA continues to maintain a shared Lenalidomide REMS that covers brand and generic products, adding certification, patient enrollment and pharmacy workflow requirements.
Iberdomide's 2026 U.S. approval and mezigdomide's late-stage regulatory progress demonstrate that cereblon-directed therapy is evolving toward more potent targeted protein degradation. These launches can offset part of the mature IMiD revenue decline.
Sources: NCI/SEER; Bristol Myers Squibb 2025 financial disclosures; U.S. FDA Lenalidomide REMS records; FDA first-generic approvals; BMS CELMoD regulatory updates.
Mature lenalidomide is becoming a price-driven multi-supplier market while new cereblon modulators seek premium positioning through deeper responses and later-line efficacy. This creates different growth economics within the same mechanism family.
FDA first-generic approvals and additional ANDAs reduce barriers to lenalidomide and thalidomide access. Wider availability can support treatment volume in cost-sensitive systems even when revenue growth is negative.
Thalidomide analogues are rarely considered in isolation; their value is tied to combinations with steroids, proteasome inhibitors, monoclonal antibodies and other myeloma agents. Successful combination evidence therefore directly affects analogue utilization.
CELMoDs such as iberdomide and mezigdomide build on cereblon modulation with greater substrate degradation and activity in resistant disease. This is shifting R&D from simple analogue substitution toward next-generation protein degradation.
Manufacturers increasingly balance generic erosion, lifecycle indications, combination partnerships, risk-management infrastructure and novel launches rather than relying on a single protected blockbuster.
Despite genericization, lenalidomide remains widely used across induction and maintenance settings. Its clinical familiarity and integration into combination regimens support high prescription volume even as price and branded share fall.
Pomalidomide is used in later-line myeloma and supports a sizable specialty franchise. Its value depends on combination evidence, treatment sequencing, competing novel mechanisms and reimbursement.
Iberdomide's 2026 U.S. approval as ZENBEXUS establishes a new commercial step beyond conventional IMiDs. Mezigdomide remains under FDA review after positive phase 3 results, signaling a broader pipeline transition.
The market is segmented into lenalidomide, pomalidomide and other analogues or next-generation cereblon modulators. Each segment has a distinct commercial profile based on lifecycle stage, treatment setting and competition.
Lenalidomide remains the largest installed analogue segment because of its broad role in multiple myeloma and other hematologic malignancies. Generic competition is rapidly reducing branded value, making this segment a volume base rather than the category's principal growth engine.
Pomalidomide remains a major later-line myeloma therapy and generated USD 2.7 billion in worldwide BMS revenue in 2025. Growth is constrained by newer therapies but supported by combination use and physician familiarity in relapsed disease.
This segment includes thalidomide, generic analogues and newer cereblon modulators such as iberdomide. The August 2026 ZENBEXUS approval creates a new premium category that can gain share even as mature analogue revenue contracts.
Multiple myeloma is the primary commercial application, with other hematologic malignancies and specialty indications contributing smaller demand pools.
Multiple myeloma dominates because immunomodulatory agents have long been integrated into induction, maintenance and relapsed-disease regimens. NCI/SEER projects 36,000 U.S. myeloma cases in 2026, supporting a persistent treated population despite intense class competition.
Lenalidomide also has roles in selected myelodysplastic syndromes and lymphoid malignancies. These indications are smaller than myeloma but diversify demand and extend the lifecycle of established analogues.
Thalidomide-related immunomodulatory effects create selected uses outside mainstream myeloma treatment, but safety controls and availability of alternatives limit broad commercial expansion in non-oncology settings.
Regional performance is shaped by treatment access, manufacturing concentration, supplement or drug utilization, reimbursement, regulatory requirements, and the maturity of distribution channels. The analysis emphasizes commercially material regional differences rather than forcing unsupported country market shares.
North America leads because of high specialty-drug utilization, broad myeloma diagnosis and treatment access, established REMS infrastructure and early adoption of new therapies. Generic lenalidomide is reducing value while novel CELMoDs restore premium growth in selected settings.
NCI/SEER estimates 36,000 new myeloma cases and 10,850 deaths in 2026. The U.S. is also the first market to approve iberdomide as ZENBEXUS, reinforcing its role in defining the next phase of cereblon-directed therapy.
Source: NCI/SEER; Bristol Myers Squibb/FDA
European markets have broad experience with lenalidomide and pomalidomide, but pricing and tender dynamics accelerate value erosion after generic entry. New therapies must demonstrate incremental benefit within country-specific HTA frameworks.
Asia-Pacific combines a large patient pool with important generic manufacturing capacity. China, Japan, India, South Korea and Australia differ substantially in reimbursement and access, creating a mix of premium innovation markets and price-sensitive volume markets.
Brazil, Mexico, Argentina and other markets depend heavily on public procurement, private insurance and generic availability. Lower-cost analogues can widen access, while premium CELMoDs will initially concentrate in major specialty centers.
GCC markets have stronger access to high-cost hematology medicines, while many African systems face diagnosis, reimbursement and specialist-capacity constraints. Generic products are likely to be more commercially important than premium new classes across much of the region.
As additional generics enter, average net price falls and branded share contracts. This can expand access while producing a negative value CAGR even if the number of treated patients remains stable or increases.
FDA requires risk-management controls for lenalidomide because of embryo-fetal toxicity. Brand and generic products participate in the Lenalidomide REMS, making certified prescribers, pharmacies and patient procedures part of commercial access.
Payers evaluate analogues within multi-drug regimens rather than as standalone products. Comparative efficacy, duration of therapy, adverse-event burden and total regimen cost determine formulary position and sequencing.
FDA listed Natco Pharma's thalidomide capsules as a first generic approval in April 2023, reinforcing the broader shift from protected analogue brands toward multi-supplier competition.
FDA accelerated approval of ZENBEXUS in August 2026 introduced a new cereblon-modulating class for relapsed or refractory multiple myeloma after at least one prior line including a proteasome inhibitor and an immunomodulatory agent.
FDA accepted Bristol Myers Squibb's mezigdomide NDA in July 2026 with a May 13, 2027 target action date, following positive SUCCESSOR-2 results. A successful launch would add another premium oral cereblon-directed therapy.
Competition is shaped by product performance, regulatory compliance, manufacturing or commercialization scale, distribution reach, price discipline, portfolio breadth, and the ability to respond to changing clinical or consumer preferences. The public overview focuses on market structure rather than reproducing company-by-company paid data.
BMS remains the key originator through Revlimid and Pomalyst/Imnovid and now extends its cereblon platform into CELMoDs. The company's challenge is to replace revenue lost to lenalidomide generics with new premium therapies and combinations.
Dr. Reddy's, Teva, Sun Pharma, Aurobindo, Viatris, Shilpa Medicare, Torrent, Hikma and other manufacturers compete through ANDA approvals, manufacturing scale, pricing and geographic reach. Their expansion supports volume but compresses market value.
Iberdomide and mezigdomide shift competition toward depth of response, activity after prior IMiDs, convenient oral dosing and combination compatibility. This may create a new premium segment even as traditional analogue revenue declines.
Pregnancy-prevention programs, pharmacy certification, prescriber support and REMS compliance add operational complexity. Manufacturers able to maintain reliable risk-management systems can protect continuity of supply and patient access.
Bristol Myers Squibb announced accelerated U.S. approval of iberdomide with daratumumab/hyaluronidase and dexamethasone for multiple myeloma after at least one prior line. The approval introduces a new premium cereblon-modulating class.
Source: Bristol Myers Squibb
The application covers mezigdomide with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. FDA assigned a target action date of May 13, 2027.
Source: Bristol Myers Squibb
BMS reported phase 3 mezigdomide combination median progression-free survival of 18 months versus 8.3 months with the comparator regimen, supporting the regulatory and commercial case for another oral CELMoD.
Source: Bristol Myers Squibb
FDA approved changes to the shared-system Lenalidomide REMS, which continues to cover relevant brand and generic products. The action underscores the lasting distribution and safety requirements attached to this therapy class.
Source: U.S. FDA
Natco Pharma received U.S. approval for thalidomide capsules in multiple strengths, adding competition to an older analogue and reinforcing access through generics.
Source: U.S. FDA
The thalidomide analogue market is forecast to decline from USD 11.14 billion in 2026 to USD 8.63 billion by 2034. The headline contraction reflects generic erosion of mature IMiDs, while the underlying treatment mechanism is being renewed through premium CELMoDs and combination-based innovation.
| Forecast Theme | 2026–2034 Direction |
|---|---|
| Lenalidomide value | Expected to decline as generic competition deepens, even if treatment volume remains substantial across induction and maintenance settings. |
| Pomalidomide | Likely to remain an important later-line oral option, but growth will be moderated by newer drug classes and evolving treatment sequences. |
| CELMoD expansion | Iberdomide and potential follow-on launches such as mezigdomide can create a premium growth pool within an otherwise contracting category. |
| Generic access | Lower-cost analogues should expand availability in emerging and budget-constrained markets, supporting volume growth but limiting revenue realization. |
| Regional mix | North America and Europe will remain innovation-heavy but value pressured, while Asia-Pacific can gain volume through generics, rising diagnosis and broader oncology access. |
2025 base year, 2026 estimate, 2034 forecast and 2026–2034 CAGR.
Commercial positioning across every segmentation dimension retained in the syndicated study.
Five-region assessment with selective country signals where authoritative evidence materially improves interpretation.
Market structure, principal companies, strategic positioning and competitive pressure points.
Demand drivers, constraints, pricing or access factors, and structural market forces.
IMiD lifecycle dynamics, genericization, REMS requirements, multiple-myeloma treatment positioning and next-generation CELMoD development.
The thalidomide analogue market assessment combines top-down market reconciliation with bottom-up analysis of product availability, treatment or consumption patterns, manufacturer positioning, regional access, and channel structure. Historical market anchors are normalized to the fixed 2025 base year, 2026 estimated year and 2034 forecast framework used throughout this report overview.
Secondary research prioritizes regulators, government agencies, pharmacopeial standards, clinical and professional bodies, peer-reviewed literature, company filings, official investor communications, product labels, and other primary sources. Exact external statistics are used selectively when they clarify demand, regulation, adoption, access, or competition.
Revenue is separated from unrelated myeloma drug classes even when therapies are used in the same combination regimen. Product-level company sales are used only as competitive and lifecycle indicators, not as substitutes for total market revenue. Generic entry, REMS requirements, treatment sequencing and new cereblon-modulator approvals are incorporated into the forecast direction.
The global market was valued at USD 11.50 billion in 2025, is estimated at USD 11.14 billion in 2026, and is projected to reach USD 8.63 billion by 2034, representing a -3.1% CAGR during 2026–2034.
The main reason is generic erosion of lenalidomide, which reduces average market value even while myeloma treatment demand remains substantial.
Multiple myeloma is the dominant application because lenalidomide, pomalidomide and newer cereblon-directed agents are used across multiple treatment stages.
North America is the largest regional market because of high specialty-treatment intensity, established reimbursement and early adoption of new myeloma therapies.
Generic lenalidomide is increasing price competition, while new CELMoDs such as iberdomide are creating a premium innovation segment within the same cereblon-directed therapeutic family.
Bristol Myers Squibb is the principal innovator, while Dr. Reddy's, Teva, Sun Pharma, Aurobindo, Viatris, Shilpa Medicare, Torrent, Hikma and other manufacturers compete in generic and regional markets.
The forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.
